BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightGene Bio-Medical Technology Co (688166.SS) as of Oct 9, 2026 is 72.23 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 290.25 M CNY — a change of -75.12% (lower).

EBITDA

72.23 MCNY

YoY

-75.12%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightGene Bio-Medical Technology Co is 2025 72.23 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightGene Bio-Medical Technology Co was 2024 290.25 M CNY. It decreases by -75.12% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
102.69 M CNY
Jan 1, 2019
142.46 M CNY
Jan 1, 2020
226.26 M CNY
Jan 1, 2021
297.60 M CNY
Jan 1, 2022
299.77 M CNY
Jan 1, 2023
288.85 M CNY
Jan 1, 2024
290.25 M CNY
Jan 1, 2025
72.23 M CNY
The BrightGene Bio-Medical Technology Co EBITDA history
YEAREBITDAYoY
72.23 MCNY-75.12%
290.25 MCNY+0.48%
288.85 MCNY-3.64%
299.77 MCNY+0.73%
297.60 MCNY+31.53%
226.26 MCNY+58.82%
142.46 MCNY+38.73%
102.69 MCNY+45.56%
70.55 MCNY+126.26%
31.18 MCNY—
Access this data via the Eulerpool API
Get Free API Key

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightGene Bio-Medical Technology Co is 72.23 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightGene Bio-Medical Technology Co changed from 290.25 M CNY to 72.23 M CNY, representing a -75.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — BrightGene Bio-Medical Technology Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BrightGene Bio-Medical Technology Co